3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Breast Neoplasms
14
Polycystic Ovary Syndrome
9
Neoplasms
5
Endometrial Neoplasms
3
Prostatic Neoplasms
2
Peripheral Nervous System Diseases
2
Obesity
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Melanoma
2
Leukemia, Myeloid, Acute
2
Leiomyoma
2
Insulin Resistance
2
Inflammation
2
Infertility, Female
2
Glioblastoma
2
Diabetes Mellitus
2
Colorectal Neoplasms
2
Cognitive Dysfunction
2
Cardiotoxicity
2
Weight Gain
1
Vomiting
1
Venous Thromboembolism
1
Vascular Malformations
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Triple Negative Breast Neoplasms
1
Thrombocythemia, Essential
1
Stem Cell Transplant Complications
1
Interventions
Cyclophosphamide
297
Rituximab
272
Etoposide
149
Filgrastim
142
fludarabine phosphate
120
Cytarabine
109
Vincristine
107
Melphalan
102
Radiotherapy
101
Doxorubicin
97
Peripheral Blood Stem Cell Transplantation
93
Methotrexate
91
fludarabine
86
Prednisone
86
Busulfan
86
Tacrolimus
66
Mycophenolic Acid
62
Granulocyte Colony-Stimulating Factor
60
Antilymphocyte Serum
58
Dexamethasone
57
Whole-Body Irradiation
55
Carmustine
54
Bortezomib
45
Cyclosporine
44
Lenalidomide
41
Methylprednisolone
40
sargramostim
39
Bendamustine Hydrochloride
37
ibritumomab tiuxetan
34
Ifosfamide
34
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Lymphoma
×
Tablets
×
Clear all
NCT06643221
2026-06-05
Allo-X
University of Arizona
Phase EARLY_PHASE1
Recruiting
200 enrolled